Table 4.
General characteristics and outcomes of the patients with and without an increase in stroke volume
| Variables | With SV increase (n = 42) | Without SV increase (n = 21) | t | P |
|---|---|---|---|---|
| Age (years) | 49.4 ± 17.0 | 52.4 ± 13.0 | −0.2 | 0.474 |
| Sex (male, %) | 47.6 | 47.6 | −0.1 | 0.924 |
| APACHE II | 16.1 ± 5.5 | 14.3 ± 4.2 | 0.3 | 0.542 |
| Mechanical ventilation (%) | 73.5 | 66.9 | 0.1 | 0.679 |
| Baseline cardiac function (%) | −0.1 | 0.982 | ||
| NYHA I | 54.8 | 52.4 | ||
| NYHA II | 35.7 | 38.1 | ||
| NYHA III | 9.5 | 9.5 | ||
| NE dose (µg·kg−1·min−1) | 0.45 ± 0.18 | 0.48 ± 0.19 | −0.1 | 0.487 |
| Maximum dose of esmolol (mg/h) | 110.6 ± 76.8 | 116.4 ± 89.9 | −0.2 | 0.237 |
| Total dose of esmolol (mg) | 197.6 ± 108.7 | 184.5 ± 113.9 | 0.2 | 0.458 |
| Time to achieve target heart rate (h) | 1.7 ± 0.3 | 1.7 ± 0.5 | 0.1 | 0.786 |
SV: Stroke volume; APACHE: Acute Physiology and Chronic Health Evaluation; NYHA: New York Heart Association; NE: Norepinephrine.